---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-044110"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:34:41.493912+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026

## Summary
- HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.
- BioCryst expects the merger with Astria Therapeutics to close in Q1 2026.
- Remaining conditions still required; deal previously announced.
- Removal of antitrust risk is a positive step toward closing.

## SEC filing metadata
- accession: 0001140361-25-044110
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000114036125044110/0001140361-25-044110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000114036125044110/ef20060538_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-044110
- JSON: https://secwatch.observer/filing/0001140361-25-044110.json
- Plain text: https://secwatch.observer/filing/0001140361-25-044110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.